92 related articles for article (PubMed ID: 12795838)
21. The prognostic value of p53 immunostaining in node-negative breast carcinoma.
Soontrapornchai P; Chanvitan A; Koontongkaew S; Sunpaweravong S
J Med Assoc Thai; 2007 Sep; 90(9):1833-8. PubMed ID: 17957927
[TBL] [Abstract][Full Text] [Related]
22. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of nuclear accumulation of p53 protein with mutations in the p53 gene on the tissues of human breast cancer].
Fan P; Wu Z; Cha X; Wang X; Wang S
Zhonghua Wai Ke Za Zhi; 1998 Nov; 36(11):655-7. PubMed ID: 11825490
[TBL] [Abstract][Full Text] [Related]
24. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius S; Börresen AL; Eyfjörd JE
Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
[TBL] [Abstract][Full Text] [Related]
25. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
[TBL] [Abstract][Full Text] [Related]
28. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
Silva JM; Silva J; Sanchez A; Garcia JM; Dominguez G; Provencio M; Sanfrutos L; Jareño E; Colas A; España P; Bonilla F
Clin Cancer Res; 2002 Dec; 8(12):3761-6. PubMed ID: 12473587
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
30. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.
Linderholm BK; Lindahl T; Holmberg L; Klaar S; Lennerstrand J; Henriksson R; Bergh J
Cancer Res; 2001 Mar; 61(5):2256-60. PubMed ID: 11280795
[TBL] [Abstract][Full Text] [Related]
31. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH
Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.
Lindahl T; Landberg G; Ahlgren J; Nordgren H; Norberg T; Klaar S; Holmberg L; Bergh J
Carcinogenesis; 2004 Mar; 25(3):375-80. PubMed ID: 14633656
[TBL] [Abstract][Full Text] [Related]
33. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL
J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497
[TBL] [Abstract][Full Text] [Related]
34. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
35. Extracellular tumor DNA in plasma and overall survival in breast cancer patients.
Garcia JM; Garcia V; Silva J; Peña C; Dominguez G; Sanchez A; Sanfrutos L; Provencio M; Millan I; Chaparro D; España P; Bonilla F
Genes Chromosomes Cancer; 2006 Jul; 45(7):692-701. PubMed ID: 16607614
[TBL] [Abstract][Full Text] [Related]
36. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of p53 tumor suppressor gene mutations and breast cancer survival.
Lai H; Ma F; Trapido E; Meng L; Lai S
Breast Cancer Res Treat; 2004 Jan; 83(1):57-66. PubMed ID: 14997055
[TBL] [Abstract][Full Text] [Related]
38. The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.
Yang CH; Cristofanilli M
Future Oncol; 2006 Apr; 2(2):247-55. PubMed ID: 16563093
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutations in breast cancer: association with ductal histology and early relapse of disease.
Brankovic-Magic MV; Jankovic RN; Dobricic JD; Borojevic ND; Magic ZM; Radulovic SS
Int J Biol Markers; 2008; 23(3):147-53. PubMed ID: 18949740
[TBL] [Abstract][Full Text] [Related]
40. The code structure of the p53 DNA-binding domain and the prognosis of breast cancer patients.
Sato K; Hara T; Ohya M
Bioinformatics; 2013 Nov; 29(22):2822-5. PubMed ID: 23986567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
